Edition:
United Kingdom

Basilea Pharmaceutica AG (BSLN.S)

BSLN.S on Swiss Exchange

36.42CHF
19 Jul 2019
Change (% chg)

CHF-0.08 (-0.22%)
Prev Close
CHF36.50
Open
CHF36.70
Day's High
CHF37.40
Day's Low
CHF35.84
Volume
70,422
Avg. Vol
46,729
52-wk High
CHF69.60
52-wk Low
CHF33.46

About

Basilea Pharmaceutica AG is a Switzerland-based company engaged in the research, development and commercialization of pharmaceutical products. The Company focuses on pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections and oncology. The Company has a range of drugs to treat drug-resistant... (more)

Overall

Beta: 1.31
Market Cap(Mil.): CHF947.87
Shares Outstanding(Mil.): 11.86
Dividend: --
Yield (%): --

Financials

  BSLN.S Industry Sector
P/E (TTM): -- 69.41 32.66
EPS (TTM): -4.21 -- --
ROI: -17.70 8.90 14.49
ROE: -- 10.04 15.79

BRIEF-Basilea Extends Phase 2 Study With Derazantinib In Intrahepatic Bile Duct Cancer

* BASILEA EXTENDS PHASE 2 STUDY WITH DERAZANTINIB IN INTRAHEPATIC BILE DUCT CANCER (ICCA) TO INCLUDE PATIENTS WITH FGFR2 GENE MUTATIONS OR AMPLIFICATIONS

01 Jul 2019

BRIEF-Basilea Pharmaceutica Publishes Clinical Data For Anticancer Drug Candidates BAL101553

* REPORTS PUBLICATION OF CLINICAL DATA FOR ANTICANCER DRUG CANDIDATES BAL101553 IN GLIOBLASTOMA AND DERAZANTINIB IN INTRAHEPATIC CHOLANGIOCARCINOMA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

03 Jun 2019

BRIEF-Basilea Pharmaceutica FY Net Loss Widens To CHF 31.4 Million

* BASILEA REPORTS STRONG REVENUE GROWTH AND SIGNIFICANT PIPELINE PROGRESS FOR FULL-YEAR 2018

19 Feb 2019

Swiss stocks - Factors to watch on Feb. 8

ZURICH/BERLIN, Feb 8 The Swiss blue-chip SMI was seen opening 0.2 percent lower at 9.018 points on Friday, according to premarket indications by bank Julius Baer .

08 Feb 2019

BRIEF-Basilea Pharmaceutica: Strong European Cresemba Sales Trigger $5 Mln Milestone Payment

* STRONG EUROPEAN CRESEMBA® (ISAVUCONAZOLE) SALES TRIGGER USD 5 MILLION MILESTONE PAYMENT TO BASILEA FROM PFIZER

08 Feb 2019

BRIEF-Basilea Says Adesh Kaul Appointed CFO

* BASILEA ANNOUNCES CHANGE IN THE MANAGEMENT COMMITTEE - ADESH KAUL APPOINTED CFO

07 Feb 2019

BRIEF-Basilea Announces Collaboration To Study Derazantinib And Atezolizumab In Urothelial Cancer

* BASILEA ANNOUNCES COLLABORATION TO STUDY DERAZANTINIB AND ATEZOLIZUMAB (TECENTRIQ®) IN UROTHELIAL CANCER

24 Jan 2019

BRIEF-Basilea Announces Collaboration To Study Derazantinib And Atezolizumab In Urothelial Cancer

* BASILEA ANNOUNCES COLLABORATION TO STUDY DERAZANTINIB AND ATEZOLIZUMAB (TECENTRIQ®) IN UROTHELIAL CANCER

24 Jan 2019

Earnings vs. Estimates